Skip to main content

Merck's Keytruda reduced risk of disease recurrence or death in early lung cancer patients by 24%

Merck plans to submit the data on early stage lung cancer to the FDA as soon as possible.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.